维普中文期刊产品整合服务
19篇 您的检索式:作者名="Cabebe E"
    题名 作者 年代 出处 被引量
1Role of anti-angiogenesis agents in treating NSCLC: focus on bevaeizumab and VEGFR tyrosine kinase inhibitors显示文摘Cabebe E Wakelee H 2007Curr Treat Options Oncol2007,8,1:1
2Sunitinib: a newly approved smallmolecule inhibitor of angiogenesis 显示文摘Cabebe E Wakelee H 2006Drugs Today (Barc)2006,42,6:1
3Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors 显示文摘Cabebe E Wakelee H 2007Curr Treat Options Oncol2007,8,1:1
4Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors显示文摘Cabebe E Wakelee H 2007Curr Treat Options Oncol2007,8,1:1
5Adjuvant treatment of resected lung cancer 显示文摘Chhatwani L Cabebe E Wakelee HA 2009Proc Am Thorac Soc2009,6,2:1
6Sunitinib: A newly approved small-molecule inhibitor of angiogenesis 显示文摘Cabebe E Wakelee H 2006Drugs of Today (Barc)2006,42,6:1
7Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors 显示文摘Cabebe E Wakelee H 2007Curr Treat Options Oncol2007,8,1:1
8Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors 显示文摘Cabebe E Wakelee H 2007Curr Treat Options Oncol2007,8,1:1
9Role of anti-angiogenesis a- gents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors显示文摘Cabebe E Wakelee H 2007Curr Treat Options Oncol2007,8,1:1
10Sunitinib:a newly approved small-molecule inhibitor of angiogenesis显示文摘Cabebe E Wakelee H 2006Drugs Today (Barc)2006,42,6:1
11Role of anti-angiogenesis agents in treating NSCLC:focus on bevacizumab and VEGFR tyrosine kinase inhibitors 显示文摘Cabebe E Wakelee H 2007Curr Treat Options Oncol2007,8,1:1
12Sunitinib:a newly app roved small2mole2 cule inhibitor of angiogenesis显示文摘Cabebe E Wakelee H 0,,:1
13Intensity-modulated radiation therapy for the spine at the University of California, Itvine显示文摘Kuo JV Cabebe E AI-Ghazi M 2002Med Dosim2002,27,2:1
14Role of anti - angiogenesis agentsin treating NSCLC : focus on bevacizumab and VEGFR tyro - sine kinase inhibitors 显示文摘Cabebe E Wakelee H 2007Curt Treat Options Oncol2007,8,1:1
15Role of anti-angiogenesis agents in treating NSCLC:Focus on bevacizumab and VEGFR tyrosine kinase inhibitors显示文摘Cabebe E Wakelee H 0,,01:1
16Sunitinib:a newly approved small-molecule inhibitor of angiogenesis显示文摘Cabebe E Wakelee H 2006Drug Today (Barc)2006,42,6:1
17Role of anti-angiogenesis agents in treating NSCLC : focus on bevacizumab and VEGFR tyrosine kinase inhibi- tors显示文摘Cabebe E Wakelee H 2007Curr Treat Options Oncol2007,8,1:1
18Role of anti-angiogenesis agents in treating NSCLC:focus on bevacizumab and VEGFR tyrosine kinase inhibitors显示文摘Cabebe E Wakelee H 0,,01:1
19Sunitinib:a newly approved small- molecule inhibitor of angiogenesis 显示文摘Cabebe E Wakelee H 2006Drug Today (Barc)2006,42,6:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费